Vir Biotechnology
VIR
VIR
209 hedge funds and large institutions have $3.25B invested in Vir Biotechnology in 2021 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 77 increasing their positions, 56 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
2.65% more ownership
Funds ownership: 57.02% → 59.67% (+2.7%)
0% more capital invested
Capital invested by funds: $3.24B → $3.25B (+$10.1M)
3% less call options, than puts
Call options by funds: $37M | Put options by funds: $38.2M
Holders
209
Holding in Top 10
7
Calls
$37M
Puts
$38.2M
Top Buyers
| 1 | +$85.1M | |
| 2 | +$45.5M | |
| 3 | +$33.6M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$20.2M |
Top Sellers
| 1 | -$135M | |
| 2 | -$43.7M | |
| 3 | -$16.7M | |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$13.4M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$12.5M |